BC
BBNX

Bruce & Co’s Beta Bionics BBNX Stock Holding History

Bruce & Co’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.52M Buy
+550,700
New +$8.15M 1.58% 22

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bruce & Co's BBNX Position: Q1 2026 in Review

Bruce & Co opened a new position in Beta Bionics (BBNX) in Q1 2026: 550,700 shares worth $5.52M. The stake represents 1.58% of the portfolio and ranks #22 among its holdings.

130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Bruce & Co held 550,700 shares of Beta Bionics worth $5.52M as of Q1 2026.
  • Beta Bionics was a new Bruce & Co position in Q1 2026.
  • Beta Bionics made up 1.58% of Bruce & Co's portfolio in Q1 2026, its #22 holding.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Bruce & Co's 13F filing for Q1 2026, filed 14 May 2026.